Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04237012 · ClinicalTrials.gov registry record · Phase 4

ACCURATE Study for Subjects With Dry Eyes

A Phase 4 study of Dry Eye Syndromes, sponsored by The Eye Centers of Racine and Kenosha.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT04237012 is a Phase 4 study of Dry Eye Syndromes that has completed, run by The Eye Centers of Racine and Kenosha. The registered enrollment target is 30 participants, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04237012, a Phase 4 study of Dry Eye Syndromes, has completed, sponsored by The Eye Centers of Racine and Kenosha.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

To determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management

Conditions Studied

Interventions

  • DRUG Dextenza 0.4Mg Intracanalicular Insert
  • OTHER Over the counter Artificial tears

Study Locations (1)

Wisconsin

  • The Eye Center of Racine - Racine

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-12-16
Est. Completion 2021-12-30
Phase Phase 4

What the Registry Record Tells You About NCT04237012

The ClinicalTrials.gov registry entry for NCT04237012 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (93% lower). The listed sponsor is The Eye Centers of Racine and Kenosha, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Dextenza 0.4Mg Intracanalicular Insert is the first listed.

NCT04237012 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT04237012 about?

NCT04237012 is a clinical study titled "ACCURATE Study for Subjects With Dry Eyes". To determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management

What is the current status of trial NCT04237012?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2019-12-16. Estimated completion is 2021-12-30.

What conditions does trial NCT04237012 study?

This clinical trial studies the following conditions: Dry Eye Syndromes.

What interventions are being tested in trial NCT04237012?

The interventions under investigation include: Dextenza 0.4Mg Intracanalicular Insert (DRUG), Over the counter Artificial tears (OTHER).

Who is sponsoring clinical trial NCT04237012?

This trial is sponsored by The Eye Centers of Racine and Kenosha, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04237012 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.